Correction: CM363, a Novel Naphthoquinone Derivative Which Acts as Multikinase Modulator and Overcomes Imatinib Resistance in Chronic Myelogenous Leukemia

Oncotarget - United States
doi 10.18632/oncotarget.26008
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Clinical Journal of Oncology Nursing
Oncology
2009English

Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Clinical Cancer Research
Cancer ResearchOncology
2008English

Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia

Haematologica
Hematology
2008English

Chronic Myelogenous Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Imatinib Mesylate Therapy May Overcome the Poor Prognostic Significance of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Cancer Acquired Resistance: A New Lesson From Chronic Myelogenous Leukemia

Journal of Bone Marrow Research
2013English

An Analysis of Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia With Imatinib-Resistant Mutations

Mathematical Biosciences
StatisticsGeneticsProbabilityMolecular BiologyBiochemistryApplied MathematicsMicrobiology SimulationImmunologyBiological SciencesMedicineAgriculturalModeling
2015English

Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy